<SEC-DOCUMENT>0001104659-13-026953.txt : 20130404
<SEC-HEADER>0001104659-13-026953.hdr.sgml : 20130404
<ACCEPTANCE-DATETIME>20130404070602
ACCESSION NUMBER:		0001104659-13-026953
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20130404
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130404
DATE AS OF CHANGE:		20130404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		13741703

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a13-9499_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>&#160;April&nbsp;4, 2013</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-50626</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91-1707622</font></b></p>    </td>   </tr>
<tr>
<td width="33%" valign="top" style="padding:0in 0in 0in 0in;width:33.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of incorporation)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.32%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">200 Connell Drive, Suite&nbsp;1500<br> Berkeley Heights, NJ 07922</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">  <br>  </font></b><font size="2" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>(908) 517-7330</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105540\13-9499-1\task5936636\9499-1-ba.htm',USER='105540',CD='Apr  4 07:45 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other Events</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;4, 2013, Cyclacel Pharmaceuticals,&nbsp;Inc. (the &#147;<b>Company</b>&#148;) issued a press release announcing that it has entered into a definitive agreement with Celgene Corporation (&#147;<b>Celgene</b>&#148;) to sell to Celgene four Cyclacel-owned patents related to the use of romidepsin injection. In connection with the agreement, Celgene has made to Cyclacel a one-time payment of $5.5 million.&#160; As a result, the litigation between Cyclacel and Celgene in the United States District Court for the District of Delaware, case number 1:10-cv-00348-GMS, is moot. Cyclacel and Celgene have filed a joint stipulation and order for dismissal requesting the Court to enter an order dismissing the litigation. A copy of the press release is attached hereto as Exhibit&nbsp;99.1 and incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neither the filing of the press release as an exhibit to this Current Report on Form&nbsp;8-K nor the inclusion in the press release of a reference to our internet address shall, under any circumstances, be deemed to incorporate the information available at our internet address into this Current Report on Form&nbsp;8-K. The information available at our internet address is not part of this Current Report on Form&nbsp;8-K or any other report filed by us with the Securities and Exchange Commission.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;9.01</font></b><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">The following exhibits are filed with this Report: </font></p>
<p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="9%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:87.76%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press   release, dated April&nbsp;4, 2013</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_074322_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105540\13-9499-1\task5936636\9499-1-ba.htm',USER='105540',CD='Apr  4 07:45 2013' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.18%;">
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.18%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.18%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="41%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   McBarron</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.9%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Vice President&#151;Finance, Chief Financial Officer and Chief Operating Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: April&nbsp;4, 2013</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_074440_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105540\13-9499-1\task5936636\9499-1-ba.htm',USER='105540',CD='Apr  4 07:45 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a13-9499_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="174" height="64" src="g94991mmi001.jpg"></font></p>    </td>
<td width="50%" valign="bottom" style="padding:0in 0in 0in 0in;width:50.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel   Pharmaceuticals,&nbsp;Inc.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="571" height="26" src="g94991mmi002.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL ANNOUNCES SALE OF FOUR CYCLACEL ROMIDEPSIN-RELATED PATENTS TO CELGENE AND</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">DISMISSAL OF ALL CLAIMS IN THEIR PATENT LITIGATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Berkeley Heights, NJ, April&nbsp;4, 2013 </font></b><font size="2" style="font-size:10.0pt;">&#150; Cyclacel Pharmaceuticals,&nbsp;Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) (&#147;Cyclacel&#148; or the &#147;Company&#148;) announced that it has entered into a definitive agreement with Celgene Corporation (&#147;Celgene&#148;) to sell to Celgene four Cyclacel-owned patents related to the use of romidepsin injection. In connection with the agreement Celgene has made to Cyclacel a one-time payment of $5.5 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a result, the litigation between Cyclacel and Celgene in the United States District Court for the District of Delaware, case number 1:10-cv-00348-GMS, is moot. Cyclacel and Celgene have filed a joint stipulation and order for dismissal requesting the Court to enter an order dismissing the litigation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are pleased to enter into this agreement with Celgene,&#148; said Spiro Rombotis, Cyclacel&#146;s President and Chief Executive Officer. &#147;The dismissal of the litigation will allow Cyclacel to concentrate on the development of our pipeline to benefit the patients we serve.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel&#146;s most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be uncertain</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&#160;&#160; 200 Connell Drive, Suite 1500, Berkeley Heights, NJ&#160; 07922 USA&#160; T: +1 (908) 517 7330 F: +1 (866) 271 3466</font></p>
<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.cyclacel.com&#160; &#150;&#160; info@cyclacel.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105732\13-9499-1\task5936531\9499-1-mm.htm',USER='105732',CD='Apr  4 07:02 2013' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form&nbsp;10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact for Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investors/Media: Corey Sohmer, (908) 517-7330, csohmer@cyclacel.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#169; Copyright 2013 Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; All Rights Reserved. The Cyclacel logo and Cyclacel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;are trademarks of Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; ISTODAX</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;is a registered trademark of Celgene Corporation.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_064357_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\105732\13-9499-1\task5936531\9499-1-mm.htm',USER='105732',CD='Apr  4 07:02 2013' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g94991mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g94991mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!``*X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^LC7O$FG
M^'K</=N6E8?NX4Y=_P#`>YH\2:]#X>TE[MP'E/R0QY^^W^`ZFO/M/T47\,OB
MCQ7<LMJQW+&>&F]`!V'H!U^E=F'P\9+VE3X?Q;[(\_%XN4'[*E\6^NR7=A/X
ML\4>))FBTF"6&+/W;9<D?[SGI^E5)_"7B";Y]2O+>)CS_I=[S_6M+^T-=\06
MS+I21:+H<?'FEA$N/=N_T%8<MAX8A8BYUV[NYOXFMK?(S]6/->K3]W2"4?)*
M[^;/#J^_[U1N7FVHKY)ZDL?ACQ#:@R:?,DVWDFRNP3^0(-6;'QQX@T2Y^SZ@
M'N%4_-%=*5D'T;K^>:STT[0IW!T[7Y+:;^$7D)C&?]]<@5=N=0U#3PECXGM?
M[0L7&8Y2P9P/[T<HZ_0U<DI^[-*7RL_E??\``S@W3]ZG)Q\T^9?.VWSN>EZ#
MXDT_Q#;E[20K*H_>0/PZ?XCW%:]>3W-K:_#K39/&CW$M[91QC[/;HFQY/,P%
M#$\`<^G;\*ZWX?>.+?Q]X=;5(+22T>*8P2PNVX!@`>&P,C##L*\+$1IQG:D[
MH^GPDZTZ5ZRL_P`_,ZNBBBL#I"BBB@`HHHH`****`"BBB@`HHHH`****`//+
MZ`^+OB$;.3+:?IB_O!V8]Q^)X^BFFWQA\3:[=7%X^SP]HV0P'`E<=0/Y?3'K
M4_A&;R/"^NZZ3B6>6:7/4C:"1^I-,M=,!\-^&]%/W=1F^TW6/XU`WD'_`,=%
M>NWRRY=N71>6EY/U/!4>>/,]>;WGYZVBO0IW2C5(8-3UQ98[!SMTW1[88>4=
MB0/Y_P`N[Y9KS3U5=^@:".JP,@EF`_VN#6L(YK[49;N$^7<W4[V5G)MS]F@C
MR'=1ZD@_F*Z6PT73]-BV6UL@8\M(PW.Y[EF/)-9SKQ@DFOE_6GSLVV:T\+*H
MVXOY]_U]$FDE;<\[G\VYM6FN['2M;LU&9)]-PD\0]<#!_2G&YTKP/X>?6-6N
M9KWPY<L@MK5K;>ZR-D@E3P,`'D=?RKLM1T_38M4M+BWM"NIEF6%X%95W;"P$
MI4<(<=3["G:;H'^E3ZGJ;-)>7T,*W-IYQEM8W0?\LU8<<]ZRJXOFARPT_K^M
M58WHX#EGSU-;?U_2=_4Y70_#'B2_\5:Q=Z]J<&H^$M1B)M=/E4LNQB&0>61A
M-HX..IY^G=:5I&G:'8)8Z79PVEJF2L4*[1D]3[GWJ[6-XI\3:?X1T&?5]1+F
M*,A5CC&7E<\*JCN37">D;-%<%;ZG\3-3A6]@T;0-.@<;DM+Z>5YR.P8H,*<>
MQJ:Z\8:KH?B[1=.UZSM8=.U:%8X[F%F/DW>!F)B>"I/W3@9R/0T`=O17(^)_
M%5Y8^(=(\.:'!!<ZM?/YDOG9*6ULOWI&P0?8>I%4]2\;ZK?>([OP]X0TF&_N
M['`O;R[E,=M;L>B<`EF]ATY]#@`[JBN7TJY\9V[W1\0V^B-;I;M)'+8/(#O'
M\+*_;&>0>U.^'_B2Y\7>"=/UR\AAAGN?,W1PYVC;(RC&23T6@#IJ*SM>UBWT
M#0+_`%:Z/[FTA:5A_>P.`/<G`_&N4^'GC?4_$T]_I^O:?#I^J6R0W"PQ9P\,
MJ!E/)/(Z'ZB@#O**Y/Q;XT.@WUEHVF:>^J:]?@FVLT<(`HZN['[JC!^N#4-C
M/\1A>VSZA9>&VLWE431V\TPEB3/)!8;6(&3C`Z4`=E17FH\6^-=8\9^(-%T"
MST+R-(DC0O?-*&8.N1]W/H?3M5OQ5XL\2^#OAW-K6I6NE2:K'.B>7;F0PE&8
M`=<-G%`'?UEMXBTI)7C>\C4J2#GU_P`_G6A!(9;>.0@`NH8@>XK)?PKI,DTD
MCVX;><L/7TR>IQT'IDT`8?AJR,G@?5=+&3(DES`1WSVJS9NDEMX2O_X%C\@D
M=`SQ8_FN/QJS8C^R/&%[:-\L&IC[3`>WF*,2+]>AIL-FD$MWX?F8QPSLUS82
M#^'G<5'NC<CV(]Z[Y3O)OOK\FK/[OT/+A3Y8Q7;3YIW7W_JB73T%M-;[^#;W
M%Q`_MYC;U/XC;^==#6#&9+B9P\:#4%0)=6S'"SH.CJ?SP>V<'VMQ7GE@(;@)
MCJMVI5E'UZ'Z_J:YZD7)W.JC)15NG](T%AB2221(T623&]@H!;'`R>]/K,%Z
MSN"DAN''2*V7Y2?]ISQC\OQK0257)3<GFJ`70-G;FLG%HWC-2V'UYE\8V6UA
M\*ZC=(6TVSUN&2[/95YP3[=?\FO3:K7]A::I83V-];QW%K.I22*095A4EDZ.
MDL:R1NKHP#*RG((/0@UA>-/#UIXG\*7VG7>5RADBE7[T4BC*N/<'],BN?B^%
M=O8I]GTKQ5XFTZQ[6EO??(@]%W`E?SKM8K%(=+2P\V5T2$0^9(VYV`7&2>Y]
MZ`//?@U!+JGA^7QAJ<[76L:LQ269@!LCC.Q47T'RY/J3[4SX031V\_BW2;GY
M-6AUF::=';YV1L;6]QP>?\:[3PCX8M?!_ANVT2SGFF@@+E7FQN.YBQS@`=ZH
M>(OA_H_B'4X]5,EYIVK1KL6_TZ<PRD=@2.&_$>U`'0ZC_P`@R[_ZXO\`^@FN
M)^"G_))-$_[;?^CGK7T3P:VDS7,USXCUO5'G@,&+ZY#H@.,E5``SQUKG].^$
MKZ181V.G>-O$UK:Q9V0Q7"*JY))P-OJ2:`*?Q=U=)KS0O"WV:\NX;JX6\U"&
MR@,TAMHVZ;1SAF[_`.S6/K7C"VMOB/X=\36^CZWI]NP.FZA)?:>\$9B<_(=Q
MXRK<X]!7ING>%+6P\57WB)KJXN;V[MX[8><01%&@Z+@9Y(R<]ZL>)_#MEXL\
M.W>BWY<6]RH!=,;D((((SW!`H`X<2II_[14C:@P5=0T816#.."P<%E!]?E8_
MC[UZ?7-ZOX)TCQ!H-GI>L+)=M9JHANRVR=&``WAEQ@G`)['TK/T_X?26-_;3
MR>+_`!-=PVTBR);3WH*-@Y`?"Y8<=":`.)TG1]>U7XK>._[$\2MHOESV_F[;
M-)_-RAQ]X\8P?SJ_\6[+4-/^"\]MJFJ'4[M+F+?=&%8B^9,CY5X&!@?A6]>_
M#!)O$6IZU8^)]<TR?475YTLYD125&!_#G_\`75O4?A[#J_@N7PUJ>N:K>1R3
M"8W<\BM,,$$+G;C''I0!UEI_QY0?]<U_E4U<7I?@&\TS4;6Z;QIXCNHX'#?9
MY[A3'(!_"PV]*[2@#.UK2O[5LPD<GDW4+B6WF`YC<=#].Q'H:I03P^(+5[&_
MC-KJ=L0SQJV'B<=)(SW!['WP:WJS]2TBWU+RY&:2&ZB_U-S"=KQ_CW'J#P:V
MA4TY7\GV_P"`85*3OS1UONN__!_KTH3R-$JQ:Y`6$9S%J%NIP/<[>8SZ]O?M
M5JW,TR9L]6@N8^WF('./JI%0K>:QIWR7UE]OB'2XLP`__`HR>O\`ND_2H)M0
M\,S$M=PQ1.3\WVBU9&S[Y6M.5O97]-5]W0QYHK=V]=']_7\?4MW3/"A.H:S%
M;QXY$2K$3^+$G\JBM+AI`(=%L]D!;=)=W"D*WJ0#\SD^IX]S4$.I^&H&#V4$
M<L@.!]FM&=L^F0M3F]UG4?ELK'[!$?\`EXO<%_\`@,8/7_>(^E'*TM5;UT7W
M=04XMZ._IJ_OZ?AZFWD;MN1G&<4M4--TJ'3A(XDDGN9L&:XF.7?'3V`'8#@5
J?KFDDGH=<6VKR5@HHHI%!1110`4444`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g94991mmi002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g94991mmi002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``:`CL!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?Z****************R-7O;B"^L;:"9(5G+!I&4'&!
M[U+HE_+?V;O-M+1RM'O08#@=Q6E67KM[/8V<36[*KR3+&689P#2:7>W$UY>6
ML[K,+<@+,BX#9'0^XK5JGJUS)::5<W$)`DC3*Y&>:@T6YEN[7S9;R*X8A21&
MH'EG'(-:=9^M7LNGZ7)<0J&<$#)&0N3U-2:9*\UH)'NX[H,<B2-=HQZ8JY6;
MKE]-IVFF>$#=O"EB,A`>Y%6-.D>6T5WNH[G<<B2-=H(^E6J***P+_4;Q=3O(
M(KF*&.WMQ*-R`[CZ$UK:?</=Z?!<2)L>1`Q7TJS6)K6HW%I?V<$5S%;QRAM\
MDB@@8K7@)-O&6D$A*C+J,!O>I*RYKZ=/$5M9*5\F2%G88YR,]ZU**P+G4KD>
M('LA>PVT2JK+O0$L3C@<UOT5A:GK$]IJT44>W[-'L^T$C)&XX%;M%8FJZE/!
MJD%FEQ':QR(6\Z1-P8_W:VESL&2"<<D=Z6L'5M2N+?6(;1+N&UA>(N9)$!&<
MFMU,[%R=QQR1WI:*********************************R]2TQK_4+&4K
M&T,);S%?N"/2M*.-(D"1HJ(.BJ,`4ZLW6M/DU&VABCV?+,KMO/!`SFDTFPGT
MTW%N2C6I<O#@_,H/4&M.JFJ6KWNF7%M$5#R)@%NE1Z3;W-M:B&XBMTV*JJ82
M3NP.IXZU?J"\%P;9A;)$\A_AESM([]*I:)IDNG0S^<R;YI"Y2/[J>PK4JM?"
MY:V(M8X9')Y6;.TCOTJKH>FR:99O'*R%Y)#(53[JY["M.BBBN?U'0);[4+JX
MW(NZ)1"V>5=?7VK;MO.^S1_:`OG!1OV'C/M4M8^K:==76H6EU;K`X@#928D`
MY_"M6'>(4\Q55]HW!.@/M3ZQ[^QO6UF"_M!`WEQ%"LK$=<^@K7&=HSC..<4M
M8DVG7JZ])?0QVTD;HJ8E)R,8Y'%;=%<]/X?GNX]0>6X99KARR*C?)@?=W<5M
MVBRI:0I.5,JH`Y4Y!-35D:W8WNHQ?9H4M3"X&7DSN0YZBM*WA^SVT4.XMY:!
M<GO@5+6+J.G7<NL0WMNEO(L<10I,2`3D^U;*YV#<`&QR!TI:************
M****@N+RWM-OGRJF[IGO4']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;
M&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&
MG_\`/TGZT?VQI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQ
MI_\`S])^M']L:?\`\_2?K1_;&G_\_2?K1_;&G_\`/TGZT?VQI_\`S])^M']L
M:?\`\_2?K2_VOIY./M2?K5VBC`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]
M*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#TH
MP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`
M]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]*,#T
BHP/2C`]*,#THP/2C`]*,#THP/2C`]*,#THP/2C`]**__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
